Hepatitis B Virus News and Research

RSS

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Vertex Pharmaceuticals Incorporated today announced that sustained virologic response (SVR) data from Study C208, which evaluated twice-daily dosing of Vertex’s investigational hepatitis C virus (HCV) protease inhibitor telaprevir, will be presented in an oral presidential plenary session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place Oct. 30 – Nov. 3, 2009 in Boston.

25 Sep 2009

Chronic viruses found living in prostate tumors

According to Dr. Ila R. Singh, an associate professor of pathology at the University of Utah, "for the first time we have analyzed prostate cancer and normal prostate tissue and found cancers are much more likely to have [the XMRV virus] ... It was also more likely to be present in more aggressive tumors," Singh said. "We found it in 20 percent of the least aggressive tumors and over 45 percent of the most aggressive tumors."

21 Sep 2009

JPO to grant patent from the Tuschl III patent series

Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the Japan Patent Office (JPO) has notified the Max Planck Society of its intent to grant a patent from the Tuschl III patent series (JP Application Number 2003-532675).

18 Sep 2009

New CLF survey on the unawareness of Canadians in contracting food-related illnesses

A new survey from the Canadian Liver Foundation (CLF) reveals more than half of Canadians over the age of 25 (57 per cent) are concerned about contracting food-related illnesses like hepatitis A, but many are unaware that their everyday food preparation and consumption habits may put them at risk for this liver disease

17 Sep 2009

Inovio’s novel platform for developing DNA based vaccines to be discussed at EmTech

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and produced by MIT’s Technology Review magazine. The conference will take place September 22nd - 24th on the MIT campus in Cambridge, MA.

16 Sep 2009

Santaris Pharma establishes its operations in the U.S.

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

16 Sep 2009

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

ChemDiv Inc. of San Diego, and iDialog (Intellektualniy Dialog) of Yaroslavl, Russia, announced today the successful completion of a pre-clinical development and the subsequent nomination of ID-12 as lead clinical development candidate for the treatment of chronic hepatitis C. This novel small molecule orally-bioavailable inhibitor of hepatitis C virus (HCV) blocks early stage of viral infection.

16 Sep 2009

Phase II trial of ANA598 commenced by Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naive HCV patients. ANA598 is an investigational, oral, non-nucleoside polymerase inhibitor.

9 Sep 2009

HCV treatment study reveals low relapse rate of Pegetron

Recently published in the New England Journal of Medicine, the largest prospective study of chronic hepatitis C virus (HCV) treatments Pegetron and Pegasys RBV (R) found both treatments equal in achieving sustained viral response. The study also found that Pegetron had a significantly lower relapse rate and is a safe and effective treatment option which has shown long term viral eradication.

9 Sep 2009

Physicians to educate Congress on the importance of reducing viral hepatitis

The National Viral Hepatitis Roundtable (NVHR) is hosting a briefing, "The Experts' Perspective: Gaps and Strategies in the Hepatitis Crisis." "Leading hepatitis physicians, one of whom is a Congressman, will be on the hill today to educate Congress on the importance of developing a strategy to reduce the significant morbidity and mortality from end-stage liver disease and liver cancer caused by chronic hepatitis B and chronic hepatitis C in the United States," said Martha Saly, Director of NVHR.

9 Sep 2009

Medtronic's COPE-HCV clinical study commences

Medtronic, Inc., today reported the initiation and first enrollments of patients in COPE-HCV (COntinuous Interferon Delivery via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV), the company’s first-ever clinical study using an external pump infusion system to treat patients with the hepatitis C virus (HCV).

3 Sep 2009

Government, medical and community experts to discuss about prevention and detection of viral hepatitis

To address this public health challenge, government, medical and community experts will meet September 10-11 in Washington, D.C. to plan an improved national response to viral hepatitis. The conference "The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C" will feature keynote addresses, panel discussions and scientific poster sessions focused on enhancing the prevention and detection of viral hepatitis and improving care for people who are already living with the disease.

2 Sep 2009

Caucasians have a higher rate of HBV recurrence compared to Asian Americans and African Americans

According to the Centers for Disease Control and Prevention (CDC) 1.5 to 2 million Americans are infected with the hepatitis B virus (HBV). Prior studies have shown there to be significant racial differences in access to and outcomes of liver transplantation. Recently, doctors from across the U.S. conducted a multicenter retrospective-prospective study of the waitlist status and outcomes of liver transplant patients with HBV infection.

28 Aug 2009

Relationship between the CD14 variation and the formation of portal lymphoid aggregates discovered

It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Age, sex, alcohol consumption and liver sensitivity to gut-derived bacterial endotoxins, were the early factors defined to enhance the risk of fibrosis progression.

27 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

Researchers discover elusive nanoscale movements of ribosomes at work

Researchers at the University of California, Berkeley, have for the first time captured elusive nanoscale movements of ribosomes at work, shedding light on how these cellular factories take in genetic instructions and amino acids to churn out proteins.

24 Aug 2009

Safe injection practices for improving safety to be discussed at the Joint Commission Infection Control Conference

Premier healthcare alliance’s Gina Pugliese, vice president of Premier’s Safety Institute, will share insights on safe injection practices to improve patient and worker safety at the Joint Commission Infection Control Conference on August 21 in Crystal City, Va.

21 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

A study published in the Proceedings of the National Academy of Sciences (PNAS) shows that the virus blocks the actions of a specific ion channel in the cell membrane that would usually trigger apoptosis - the cell's self-destruct programme - and in doing so, has evolved another way of protecting itself from being eliminated from the body.

19 Aug 2009

Hepatitis B Virus News and Research

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Chronic viruses found living in prostate tumors

JPO to grant patent from the Tuschl III patent series

New CLF survey on the unawareness of Canadians in contracting food-related illnesses

Inovio’s novel platform for developing DNA based vaccines to be discussed at EmTech

Santaris Pharma establishes its operations in the U.S.

Pre-clinical studies of ID-12 orally-bioavailable inhibitor completes

Phase II trial of ANA598 commenced by Anadys Pharmaceuticals

HCV treatment study reveals low relapse rate of Pegetron

Physicians to educate Congress on the importance of reducing viral hepatitis

Medtronic's COPE-HCV clinical study commences

Government, medical and community experts to discuss about prevention and detection of viral hepatitis

Caucasians have a higher rate of HBV recurrence compared to Asian Americans and African Americans

Relationship between the CD14 variation and the formation of portal lymphoid aggregates discovered

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Researchers discover elusive nanoscale movements of ribosomes at work

Safe injection practices for improving safety to be discussed at the Joint Commission Infection Control Conference

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News